Brain tumor drug trial fizzles: only 3 patients enrolled
NCT ID NCT05029960
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether brivaracetam, a seizure medication, is safe for people with diffuse gliomas (a type of brain tumor). Only 3 participants were enrolled before the study was terminated. The main goal was to track side effects, not to measure tumor shrinkage or survival. Because it ended early, no strong conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brivaracetam (a seizure drug)
- What this could lead to
- If it works, this could point toward a way to manage brain tumor symptoms safely.
- What could go wrong
- This was a very early, tiny trial (only 3 people) that ended early. It cannot prove effectiveness, and the drug may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Can a targeted pill slow brain tumor growth after surgery?
- Digital tests may offer a new way to track brain health in tumor patients
- Mapping the hidden toll of brain radiation on young minds
- Scientists create detailed brain maps to protect language during surgery
- Could a cancer drug shrink recurrent brain tumors?